Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2011-01-18
2011-01-18
Desai, Rita J (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C546S115000, C546S272100, C514S256000, C514S302000, C514S338000
Reexamination Certificate
active
07872128
ABSTRACT:
The present invention comprises a new class of compounds capable of modulating the c-kit protein kinase and, accordingly, useful for treatment of c-kit mediated diseases including, without limitation, autoimmune disease, allergies, mastcytosis, mast cell related tumors and various fibrotic diseases. The compounds have a general Formula Iwherein R1-5, X, Y and Z are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
REFERENCES:
patent: 6271233 (2001-08-01), Brazzell
patent: 2005/0043347 (2005-02-01), Betschmann
Bunnet, J. F. et. al. “Aromatic Nucleophilic Substitution Reactions” Chemical Reviews 1951, 49, 273-412.
Michelotti et. al. “Two classes of p38a MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes” Bioorganic & Medicinal Chemistry Letters 2005, 15, 5274-5279.
Jiang et. al. “3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors.” Bioorganic & Medicinal Chemistry Letters 2007, 17, 6378-6382.
Liu et. al. “Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors” Bioorganic & Medicinal Chemistry Letters 2006, 16, 2590-2594.
Miyazaki et. al. “Design and effective synthesis of novel templates, 3,7-diphenyl-4- amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases” Bioorganic & Medicinal Chemistry Letters 2007, 17, 250-254.
Mulvihill et. al. “Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors” Bioorganic & Medicinal Chemistry 2008, 16, 1359-1375.
Mulvihill et. al. “1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors” Bioorganic & Medicinal Chemistry Letters 2007, 17, 1091-1097.
Kunz et. al. “Discovery of amido-benzisoxazoles as potent c-Kit inhibitors.” Bioorganic & Medicinal Chemistry Letters 18 (2008) 5115-5117.
Kirshenbaum et al., Blood 94:2333-2342, 1999.
Ishizaka et al, Curr. Opinion Immunol. 5:937-943, 1993.
Bradding et al., J. Immunol. 155:297-307, 1995.
Irani et al., J. Immunol. 147:247-253, 1991.
Boissan and Arock, J. Leukoc. Biol. 67:135-148, 2000.
Watanabe et al., Blood 11:3855-3866, 1994.
Yammaguchi et al., Hematology 29:133-139, 1999.
Secor et al., J. Experimental Medicine 191:813-822, 1999.
Andoh et al, Clinical & Experimental Immunology 116:90-93, 1999.
Mauduit et al, Human Rep. Update 5: 535-545, 1999.
Blume-Jensen et al, Nature Genetics 24:157-162, 2000.
Feng et al, Fertility and Sterility 71:85-89, 1999.
Parrott and Skinner, Endocrinology 140:4262-4271, 1999.
Aldenborg and Enerback, Histochem. J. 26:587-596, 1994.
Hooks et al., Blood 11:3855-3866, 1994.
Chen Ning
Hu Essa
Kunz Roxanne
Rumfelt Shannon
Tasker Andrew
Amgen Inc.
Desai Rita J
O'Dell David K
Prabhakar Reddy G.
LandOfFree
Benzisoxazole and isoxazolo-pyridine compounds and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzisoxazole and isoxazolo-pyridine compounds and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzisoxazole and isoxazolo-pyridine compounds and method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2652130